BioCentury
ARTICLE | Clinical News

KU-046: Phase I started

January 7, 2013 8:00 AM UTC

Kareus said that CRO Quintiles began a 2-part, double-blind, placebo-controlled, U.S. Phase I trial to evaluate single and multiple ascending-doses of oral KU-046 in 54 healthy volunteers. In June 201...